Sanofi Submits NDA for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

PARIS, Dec. 23, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news